Kathmere Capital Management LLC Purchases 195 Shares of Johnson & Johnson (NYSE:JNJ)

Kathmere Capital Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,242 shares of the company’s stock after buying an additional 195 shares during the quarter. Kathmere Capital Management LLC’s holdings in Johnson & Johnson were worth $2,192,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Peak Asset Management LLC grew its position in shares of Johnson & Johnson by 9.3% during the first quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after purchasing an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Johnson & Johnson by 0.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after buying an additional 6,836 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its position in shares of Johnson & Johnson by 21.8% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after buying an additional 161,687 shares during the last quarter. Tekla Capital Management LLC boosted its position in shares of Johnson & Johnson by 12.8% during the first quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock worth $111,876,000 after acquiring an additional 82,100 shares during the last quarter. Finally, Wisconsin Capital Management LLC grew its stake in Johnson & Johnson by 0.8% during the first quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after acquiring an additional 127 shares in the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Citigroup initiated coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. Stifel Nicolaus increased their target price on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 8th. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Finally, Atlantic Securities raised their target price on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $170.65.

Johnson & Johnson Price Performance

JNJ opened at $162.41 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The business’s fifty day simple moving average is $166.21 and its 200-day simple moving average is $161.83. The company has a market capitalization of $422.10 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 3.26 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the firm posted $2.59 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10.03 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were issued a $1.19 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.